Millipore's Bioscience Division Highlights Strategy and New Products at ACHEMA 2006 Conference

Company Focused on Extending Leadership by Improving Laboratory Productivity; Introduces New Ultrapure Water System

BILLERICA, Mass.--(BUSINESS WIRE)--May 16, 2006--Millipore Corporation (NYSE:MIL), a leading provider of products and services that improve productivity in the laboratory and in biopharmaceutical manufacturing, today highlighted its strategy for improving customer productivity in clinical, analytical, and research laboratories at the ACHEMA 2006 Conference in Frankfurt, Germany. As part of the Company's effort to accelerate new product launches, Millipore also featured Milli-Q(R) Advantage, a new ultrapure water system, at the conference.

Milli-Q(R) Advantage provides a convenient, flexible system for users to produce and dispense ultrapure water on demand for a variety of laboratory applications. It creates additional bench space in the laboratory by combining four separate systems that were designed for individual applications into one integrated system. Milli-Q(R) Advantage, which can be placed on the bench, under the bench, or on a wall, notifies the user about consumable usage to ensure proper maintenance and optimal performance. It is the only product in the market that offers customers an integrated, remote dispenser and display, which optimizes performance and flexibility.

"Millipore's Bioscience Division is a leader in developing solutions that improve productivity. We empower our customers with the right products for the right applications, so they can spend more time on scientific research and reduce the time required for sample preparation," said Dominque Baly, President of Millipore's Bioscience Division. "The expertise of our customer support and global field organization is unmatched in the industry and enables our customers to have confidence in using our products for consistently and reliably reproducing results and maximizing efficiency."

As part of its strategic effort to broaden the product portfolio of the Bioscience Division, Millipore recently announced that it intends to acquire Serologicals Corporation. The acquisition will strengthen Millipore's Bioscience Division by giving it leading positions in a broad range of high growth segments such as drug discovery products and services, antibodies, cell biology reagents, and stem cell research. This expanded offering will enable Millipore to advance its customers' research by optimizing workflows from sample preparation, developing and performing assays, and analyzing results.

Baly added, "For more than fifty years, we have led the industry in product quality and technical innovation. As we execute our long-term strategy, we expect to bring new innovative solutions to the market and further expand our product portfolio. With the addition of new capabilities we will gain from Serologicals, we will have substantial resources to invest in new technologies that address the needs of our customers."

About Millipore

Millipore is a leading bioprocess and bioscience products and services company, organized into two divisions. The Bioprocess division offers solutions that optimize development and manufacturing of biologics. The Bioscience division provides high performance products and application insights that improve laboratory productivity. Millipore has a deep understanding of its customers' research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company employs approximately 4,800 people worldwide and reported revenues of $991 million in 2005. For additional information on Millipore Corporation, please visit its website at: www.millipore.com.

This material is not a substitute for the proxy statement Serologicals will file with the Securities and Exchange Commission. Investors are urged to read the proxy statement when it becomes available, because it will contain important information. The proxy statement and other documents which will be filed by Serologicals with the Securities and Exchange Commission will be available on the SEC's website, www.sec.gov. Serologicals and certain of its directors, executive officers and certain other members of its management may be deemed to be soliciting proxies from Serologicals' shareholders in connection with the proposed transaction. Investors may obtain a detailed list of names, affiliations and interests of Serologicals participants in the solicitation of proxies of Serologicals shareholders by reading the proxy statement when it becomes available.

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, failure to achieve design wins in our pharmaceutical and biotechnology customers' manufacturing design phase for a particular drug precluding any sales of our products to those customers for those particular drugs; suspension or termination of a customer's volume production; lack of availability of raw materials or component products on a timely basis; regulatory delay in the approval of new therapeutics, and their ultimate commercial success; the inability to establish and maintain necessary product and process quality levels; the inability to realize the expected benefits of development, marketing and other alliances; competitive factors such as new membrane or chromatography technology; the inability to identify or successfully integrate acquired businesses; difficulties inherent in research and development activities; the failure to attract and retain critical personnel; the inability to achieve anticipated cost benefits of our supply chain initiative; risks relating to our concentration of principal manufacturing operations; the inability to utilize technology in current or planned products due to overriding rights by third parties; potential environmental liabilities; conditions in the economy in general and in the bioscience and bioprocess markets in particular; foreign exchange fluctuations; reduced private and government research funding; exposure to product liability claims; and difficulties inherent in transferring or outsourcing of manufacturing operations. Please refer to our filings with the SEC, including our most recent Annual Report on Form 10-K, for more information on these and other risks that could cause actual results to differ.

CONTACT: Millipore Corporation
Investor contact
Joshua Young, 978-715-1527 or 800-225-3384
Director, Investor Relations
joshua_young@millipore.com
or
Media Contact:
Thomas Anderson, 978-715-1043 or 800-225-3384
Vice President
Corporate Communications
thomas_anderson@millipore.com

SOURCE: Millipore Corporation

Sustainability

Our commitment to environmental stewardship.

» More

Find A Location

Find the Millipore office or expert closest to you.

Contact Us

We want to hear from you. Contact a specific department below or click "Suggestions and Feedback" to send your comments.